Sued Eustáquio Mendes Miranda

Mr. Sued Eustáquio Mendes Miranda

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SNShirleide Santos Nunes
Shirleide Santos Nunes
Juliana de Oliveira SilvaJuliana de Oliveira Silva
Juliana de Oliveira Silva
RFRenata Salgado Fernandes
Renata Salgado Fernandes
SMSued Eustáquio Mendes Miranda
Sued Eustáquio Mendes Miranda
ELElaine Amaral Leite
Elaine Amaral Leite
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
PEGylated liposomes are largely studied as long-circulating drug delivery systems. Nevertheless, the addition of PEG can result in reduced interactions between liposomes and cells, hindering liposomal internalization into target cells. The presence of PEG on the surface of pH-sensitive liposomes is not advantageous in terms of biodistribution and tumor uptake, raising the question of whether the indiscriminate use of PEG benefits the formulation. In this study, two doxorubicin-loaded pH-sensitive liposomal formulations, PEGylated (Lip2000-DOX) or non-PEGylated (Lip-DOX), were prepared and characterized. Overall, the PEGylated and non-PEGylated liposomes showed no differences in size or morphology in Cryo-TEM image analysis. Specifically, DLS analysis showed a mean diameter of 140 nm, PDI lower than 0.2, and zeta potential close to neutrality. Both formulations showed an EP higher than 90%. With respect to drug delivery, Lip-DOX had better cellular uptake than Lip2000-DOX, suggesting that the presence of PEG reduced the amount of intracellular DOX accumulation. The antitumor activities of free-DOX and both liposomal formulations were evaluated in 4T1 breast tumor-bearing BALB/c mice. The results showed that Lip-DOX was more effective in controlling tumor growth than other groups, inhibiting tumor growth by 60.4%. Histological lung analysis confirmed that none of the animals in the Lip-DOX group had metastatic foci. These results support that pH-sensitive liposomes have interesting antitumor properties and may produce important outcomes without PEG.

29 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DSDarline B. dos Santos
Darline B. dos Santos
JLJanaina Alcantara Lemos
Janaina Alcantara Lemos
SMSued Eustáquio Mendes Miranda
Sued Eustáquio Mendes Miranda
LFLeonardo D. Di Filippo
Leonardo D. Di Filippo
Jonatas DuarteJonatas Duarte
Jonatas Duarte
AOAnna Oliveira
Anna Oliveira
Leishmania is a trypanosomatid that causes leishmaniasis. It is transmitted to vertebrate hosts during the blood meal of phlebotomine sandflies. The clinical manifestations of the disease are associated with several factors, such as the Leishmania species, virulence and pathogenicity, the host–parasite relationship, and the host’s immune system. Although its causative agents have been known and studied for decades, there have been few advances in the chemotherapy of leishmaniasis. The urgency of more selective and less toxic alternatives for the treatment of leishmaniasis leads to research focused on the study of new pharmaceuticals, improvement of existing drugs, and new routes of drug administration. Natural resources of plant origin are promising sources of bioactive substances, and the use of ethnopharmacology and folk medicine leads to interest in studying new medications from phytocomplexes. However, the intrinsic low water solubility of plant derivatives is an obstacle to developing a therapeutic product. Nanotechnology could help overcome these obstacles by improving the availability of common substances in water. To contribute to this scenario, this article provides a review of nanocarriers developed for delivering plant-extracted compounds to treat clinical forms of leishmaniasis and critically analyzing them and pointing out the future perspectives for their application.

14 November 2022 in Polymers
Verified
Journal Article
Open access
PDF file
FCFernanda Lapa Campos
Fernanda Lapa Campos
JLJanaina Alcantara Lemos
Janaina Alcantara Lemos
Caroline Mari Ramos OdaCaroline Mari Ramos Oda
Caroline Mari Ramos Oda
Juliana de Oliveira SilvaJuliana de Oliveira Silva
Juliana de Oliveira Silva
RFRenata Salgado Fernandes
Renata Salgado Fernandes
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
Colorectal cancer has been considered a worldwide public health problem since current treatments are often ineffective. Irinotecan is a frontline chemotherapeutic agent that has dose-limiting side effects that compromise its therapeutic potential. Therefore, it is necessary to develop a novel, targeted drug delivery system with high therapeutic efficacy and an improved safety profile. Here, micellar formulations composed of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-mPEG2k) containing irinotecan were proposed as a strategy for colorectal cancer therapy. Firstly, the irinotecan-loaded micelles were prepared using the solvent evaporation method. Then, micelles were characterized in terms of size, polydispersity, zeta potential, entrapment efficiency, and release kinetics. Cytotoxicity and in vivo antitumor activity were evaluated. The micelles showed size around 13 nm, zeta potential near neutral (−0.5 mV), and encapsulation efficiency around 68.5% (irinotecan 3 mg/mL) with a sustained drug release within the first 8 h. The micelles were evaluated in a CT26 tumor animal model showing inhibition of tumor growth (89%) higher than free drug (68.7%). Body weight variation, hemolytic activity, hematological, and biochemical data showed that, at the dose of 7.5 mg/kg, the irinotecan-loaded micelles have low toxicity. In summary, our findings provide evidence that DSPE-mPEG2k micelles could be considered potential carriers for future irinotecan delivery and their possible therapeutic application against colorectal cancer.

30 January 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
WBWeslley Fernandes Braga
Weslley Fernandes Braga
EAEdenil Costa Aguilar
Edenil Costa Aguilar
JNJuliana Maria Navia-Pelaez
Juliana Maria Navia-Pelaez
DÁDanielle de Lima Ávila
Danielle de Lima Ávila
LRLuisa Rezende
Luisa Rezende
Jacqueline Isaura Alvarez-LeiteJacqueline Isaura Alvarez-Leite
Jacqueline Isaura Alvarez-Leite

10 July 2025 in Chemistry & Biodiversity
Verified
Journal Article
Open access
DSDaniel Soares
Daniel Soares
DVDaniel Bragança Viana
Daniel Bragança Viana
ABAndré Luis Branco de Barros
André Luis Branco de Barros
SMSued Eustáquio Mendes Miranda
Sued Eustáquio Mendes Miranda
Daniela SachsDaniela Sachs
Daniela Sachs
EEEryvaldo Socrates Egito
Eryvaldo Socrates Egito
Lupeol is a natural product commonly found in many vegetables and fruits in significant quantities. Previous studies have demonstrated the relevant activity of lupeol against various tumor cell lines, suggesting that the natural product could be a promising agent for cancer treatment. Due to bioavailability requirements, lupeol presents a challenge for internal administration in therapeutic doses. Thus, the development of pharmaceutical formulations, particularly nanostructured systems, could represent an important alternative to improving the bioavailability of the molecule. This study developed and characterized a liposomal formulation loaded with lupeol, exhibiting substantial cytotoxic, cytostatic, and apoptotic profiles against the MDA‐MB‐231 tumor cells, a triple‐negative human breast cancer subtype. Toxicological in vivo evaluations revealed a nonrelevant toxic profile against healthy mice. Considering all the results obtained, the present study revealed important potentialities of the liposomal system, constituting a potential therapeutic alternative against triple‐negative breast cancer.

4 December 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
BOBárbara Bruna Ribeiro de Oliveira-Mendes
Bárbara Bruna Ribeiro de Oliveira-Mendes
SMSued Eustáquio Mendes Miranda
Sued Eustáquio Mendes Miranda
DSDouglas Ferreira Sales-Medina
Douglas Ferreira Sales-Medina
BMBárbara de Freitas Magalhães
Bárbara de Freitas Magalhães
YKYan Kalapothakis
Yan Kalapothakis
CHCarolina Campolina Rebello Horta
Carolina Campolina Rebello Horta
Background: The hyaluronidase enzyme is generally known as a spreading factor in animal venoms. Although its activity has been demonstrated in several organisms, a deeper knowledge about hyaluronidase and the venom spreading process from the bite/sting site until its elimination from the victim's body is still in need. Methods and principal findings: We used technetium-99m radiolabeled Tityus serrulatus venom (99mTc-TsV) to evaluate the venom distribution kinetics in mice. To understand the hyaluronidase’s role in the venom’s biodistribution, 99mTc-TsV was immunoneutralized with specific anti-T.serrulatus hyaluronidase serum. Venom biodistribution was monitored by scintigraphic images of treated animals and by measuring radioactivity levels in tissues as heart, liver, lungs, spleen, thyroid, and kidneys. In general, results revealed that hyaluronidase inhibition delays venom components distribution, when compared to the non-neutralized 99mTc-TsV control group. Scintigraphic images showed that the majority of the immunoneutralized venom is retained at the injection site, whereas non-treated venom is quickly biodistributed throughout the animal’s body. At the first 30 minutes, concentration peaks are observed in the heart, liver, lungs, spleen, and thyroid, which gradually decreases over time. On the other hand, immunoneutralized 99mTc-TsV takes 240 minutes to reach high concentrations in the organs. A higher concentration of immunoneutralized 99mTc-TsV was observed in the kidneys in comparison with the non-treated venom. Further, in situ neutralization of 99mTc-TsV by anti-T.serrulatus hyaluronidase serum at zero, ten, and 30 minutes post venom injection showed that late inhibition of hyaluronidase can still affect venom biodistribution. In this assay, immunoneutralized 99mTc-TsV was accumulated in the bloodstream until 120 or 240 minutes after TsV injection, depending on anti-hyaluronidase administration time. Altogether, our data show that immunoneutralization of hyaluronidase prevents venom spreading from the injection site. Conclusions: The results obtained in the present work show that hyaluronidase has a key role not only in the venom spreading from the inoculation point to the bloodstream, but also in venom biodistribution from the bloodstream to target organs. Our findings demonstrate that hyaluronidase is indeed an important spreading factor of TsV, and its inhibition can be used as a novel first-aid strategy in envenoming.